Show simple item record

dc.contributor.authorBarbosa, Cassia Maria Passarelli Lupoli [UNIFESP]
dc.contributor.authorTerreri, Maria Teresa Ramos Ascensão [UNIFESP]
dc.contributor.authorRosario, P. O. [UNIFESP]
dc.contributor.authorMoraes-Pinto, Maria Isabel de [UNIFESP]
dc.contributor.authorSilva, C. A. A.
dc.contributor.authorHilário, Maria Odete Esteves [UNIFESP]
dc.date.accessioned2018-06-15T16:52:44Z
dc.date.available2018-06-15T16:52:44Z
dc.date.issued2012-09-01
dc.identifierhttp://www.clinexprheumatol.org/abstract.asp?a=5209
dc.identifier.citationClinical And Experimental Rheumatology. Pisa: Clinical & Exper Rheumatology, v. 30, n. 5, p. 791-798, 2012.
dc.identifier.issn0392-856X
dc.identifier.urihttp://repositorio.unifesp.br/11600/43332
dc.description.abstractObjectivesThe aim of the present paper is to evaluate the immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.MethodsWe performed a prospective and controlled study on a group of 54 SLE patients that were chosen at random to be or not to be vaccinated (28 were vaccinated and 26 were not). Twenty-eight healthy controls, of matching age and sex were also vaccinated. All were submitted to a questionnaire, physical evaluation and laboratory assays: lymphocyte immuno-phenotyping by flow cytometry, plasma varicella zoster virus (VZV) serology by ELISA and in vitro interferon gamma (IFN gamma) production by T-cells after stimulus with VZV antigen. They were evaluated before vaccination and at 30, 45, 180 and 360 days afterwards.ResultsWe did not observe any differences in the frequency of adverse events in both vaccinated groups. At study entry, all individuals were seropositive for VZV antibodies. The serum VZV antibody titres similarly increased after vaccination. The frequency of flares and the SLEDAI score were also similar among the patients. Thirty days after vaccination the production of IFN gamma specific to VZV was lower in the SLE group compared to healthy, controls. In the follow-up we observed 4 cases of herpes zoster in the SLE unvaccinated group, but no zoster in the vaccinated group.ConclusionThe varicella vaccine was well tolerated in SLE group, who had pre-existing immunity to varicella. The varicella vaccine immunogenicity measurement by serum antibody titres was appropriate. The incidence of HZ was lower in the vaccinated lupus group.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent791-798
dc.language.isoeng
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical And Experimental Rheumatology
dc.rightsAcesso restrito
dc.subjectherpes zosteren
dc.subjectimmunocompromised hosten
dc.subjectsystemic lupus erythematosusen
dc.subjectvaccineen
dc.subjectvaricellaen
dc.titleImmune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virusen
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.description.affiliationUniv Fed Sao Paulo, Disciplina Alergia Imunol Clin & Reumatol, Dept Pediat, BR-04025002 Sao Paulo, Brazil
dc.description.affiliationUniv Fed Sao Paulo, Div Paediat Infect Dis, Dept Pediat, BR-04025002 Sao Paulo, Brazil
dc.description.affiliationUniv Sao Paulo, Childrens Inst, Dept Paediat, Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Disciplina Alergia Imunol Clin & Reumatol, Dept Pediat, BR-04025002 Sao Paulo, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Paediat Infect Dis, Dept Pediat, BR-04025002 Sao Paulo, Brazil
dc.description.sponsorshipIDFAPESP: 05/55003-8
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000310828600024


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record